Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.

Abstract: Disclosed are compositions for the treatment of emotional pain, physical pain, and insomnia comprising a compound comprising an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4). Examples of opioid antagonist include naltrexone and naloxone, and their use in the treatment, prevention, and reversal of pain.

Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.

Abstract: Provided are superabsorbent materials composed of agar, and one or more water-soluble natural polysaccharides, and dietary compositions containing such superabsorbent materials. The disclosed superabsorbent materials have various food and therapeutic applications and can be used as loading vehicles for nutrients and therapeutic agents. Also provided are methods for preparing such superabsorbent materials.

Abstract: The present disclosure relates to a culturing patch, culturing method, culture test method, culture test device, drug test method, and drug test device, and the culturing patch according to an aspect of the present disclosure includes component required for growth of an object to be cultured, and a mesh structural body provided in a mesh structure forming micro-cavities in which the component required for growth are contained that is configured to come into contact with a reaction region in which the object to be cultured is placed and provide some of the contained component required for growth to the reaction region.

Abstract: The present invention relates to storage stable emulsion formulations of meloxicam or its pharmaceutically acceptable salts, solvates and hydrates thereof suitable for parenteral administration.

Abstract: A method for reducing the appearance of a skin pore in skin of a subject in need thereof is disclosed. The method can include topically applying to the skin pore a composition comprising effective amount of Albizia julibrissin bark extract, and hydrolyzed soy flour, wherein topical application of the composition reduces the appearance of the size of the skin pore.

Abstract: Provided is a production method for a gel composition including steps (1) to (3) mentioned below: step (1) of mixing at room temperature a partial degradation product of the galactose moiety of galactoxyloglucan and an aqueous solvent to obtain a mixture; step (2) of cooling or freezing the mixture obtained in step (1); and step (3) of gelling the mixture cooled or frozen in step (2) by heating to obtain a gel composition that includes the galactose-partial degradation product.

Abstract: The present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.

Abstract: A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-? inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

Abstract: The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: The present invention pertains to a complex including nanoparticles and, carried on the surface of the nanoparticles, a lysosomal enzyme inhibitor or kinase inhibitor shown by general formula (A) and a phospholipid mimetic substance shown by general formula (B). In general formula (A), n1 is an integer of 2-30, n2 is an integer of 2-30, the -S- terminal is a nanoparticle-carrying site, and R10 is a suicide substrate site or a kinase inhibition site. In general formula (B), n3 is an integer in the range of 2-30, and the -S- terminal is a nanoparticle-carrying site. The present invention provides a versatile system capable of efficiently delivering a drug to endolysosomes and allowing the drug to function at a low concentration on lysosomal enzymes, and an anticancer agent in which this system is used.

Abstract: Described is a method to fabricate a gold/mesoporous silica hybrid nanoparticle. According to the process, a gold nanoparticle can be conjugated onto the surface of a mesoporous silica nanoparticle to yield a photothermal stable theranostic platform, gold/mesoporous silica hybrid nanoparticle. The nanoparticles can be useful for disease detection, treatment, and monitoring.

Abstract: The present invention relates to pharmaceutical compositions with mucoadhesive and sustained release characteristics containing the association of the extract or fractions of Curcuma longa L. with curcuminoid content greater than 5% and Bidens pilosa (Bd) extract, which has an important proliferative and anti-inflammatory effect, for the treatment of inflammatory diseases of the oral cavity (stomatitis) and of the gastrointestinal tract, as, for example, mucositis induced by radiotherapy and/or chemotherapy and aphthous lesions. Additionally, inflammatory skin lesions and vaginal mucositis. These are compositions obtained from a liquid base formulation containing an aqueous-based solvent system. The subject of the present invention is, therefore, to obtain pharmaceutical preparations, to develop their obtainment processes and to establish their uses.

Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

Abstract: The present invention relates to the use of hyaluronidase for the prevention and/or treatment of cardiac insufficiency. In addition, the present invention provides a composition and a combined preparation each comprising hyaluronidase and at least one further antihypertensive, and a method of prevention and/or treating cardiac insufficiency in a patient in need thereof, wherein the patient is administered a therapeutically effective amount of hyaluronidase.

Abstract: The present invention relates to an anhydrous composition in aerosol form comprising, in particular in a physiologically acceptable medium: a) an oily phase comprising i) at least one volatile oil, and ii) at least one nonvolatile hydrocarbon-based oil, and iii) at least one phenyl silicone, and b) at least one antiperspirant active agent chosen from aluminum and/or zirconium salts or complexes, c) at least one water-insoluble film-forming block ethylenic polymer d) at least one propellant. The invention also relates to a cosmetic process for treating human perspiration, and optionally the body odors associated with human perspiration, especially underarm odors, comprising the application of said composition to a surface of the skin.

Abstract: A method for combining energy supplements such as energy drinks or food items with Cannabis extract. The energy supplements include at least one energizing active ingredient of variable potency. The Cannabis extract may be produced of variable potency from at least one strain of Cannabis. The agglomerated product may be produced in various forms of food or beverages. When used, the agglomerated product may provide the typical effects of Cannabis in addition to the added energy and focus provided by energy supplements.

Abstract: A method for extracting nucleic acids from a biological sample by isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction, and extracting nucleic acids from the isolated particles. The centrifugation procedures are performed at a speed not exceeding about 200,000 g. The extracted nucleic acids contain both 18S and 28S rRNA.

Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.

Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Abstract: A slip form paver machine includes a slip form mold and left and right side form assemblies closing the slip form mold on the sides. Each side form assembly includes a mounting portion, a side form, and a side form actuator configured to move the side form up and down relative to the mounting portion to adjust a height of the side form relative to the ground surface. At least one side form height sensor is configured to detect the height of the side form. A controller is configured to receive input signals from the side form height sensors and to send control signals to the side form actuators to control the height of the side forms relative to the ground surface.

Abstract: In one embodiment, a composition may include beeswax, Candelilla wax, oregano oil, glycerin, olive oil, arnica plant concentrate, and carbolic acid. In another embodiment, a method for treating an injury to an affected limb may include may include cleaning the affected limb, providing a water-based treatment composition, applying the water-based treatment composition to the affected limb, providing an oil-based treatment composition, and applying the oil-based treatment composition to the affected limb. The method may further include providing a gauze impregnated with a wax-based treatment composition and wrapping the impregnated gauze around the affected limb. The water-based treatment composition may include water, essence of oregano, and carbolic acid. The oil-based treatment composition may include glycerin, arnica plant concentrate, and carbolic acid. The wax-based treatment composition may include beeswax, Candelilla wax, arnica plant concentrate, and carbolic acid.

Abstract: A mixture of honey solution and a surgical adhesive, typically a cyanoacrylate adhesive is described. The adhesive and honey solution are mixed and applied to a cut or wound prior to the cure of the mixture. The adhesive mixture, which retains the strength of the unadulterated adhesive significantly reduces the growth of bacteria in the vicinity of the associated closed cut or wound, has applicability in both human and veterinary medicine.

Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.

Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.

Abstract: A non-porous composite is provided that includes a textile substrate impregnated with a first fluoropolymer and a film of polymeric material comprising at least one second fluoropolymer filled with porous particles of a silicate having a granulometric dimension d50 less than or equal to 5 ?m and a porosity ranging from 30 to 60% in volume and loaded with antibacterial ions of at least one metal selected from the group consisting of silver, copper, zinc and nickel. A method for production of the composite and a containing and/or transport element for a fluid, preferably water, produced with the composite, are also provided.

Abstract: A composite element and methods of fabrication thereof are provided. The composite element can include a binder material and one or more electrical traces supported by the binder material, where a composition of the binder material is a thermoresponsive material and where each of the one or more electrical traces comprises an interconnected network of nanoparticles.

Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject having reduced kidney function.

Abstract: A deodorant stick comprising: at least about 25% of a liquid triglyceride; at least one antimicrobial; a primary structurant with a melting point of at least about 50° C.; and less than 8% of secondary structurants having a melting point of at least about 60° C.; said stick being free of an aluminum salt; and said stick having a hardness from about 80 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.

Abstract: Provided is a method for producing HPMCP capable of reducing the average particle size of HPMCP particles to an intended range without a pulverization step. Specifically provided is a method for producing hypromellose phthalate, comprising an esterification step of reacting hypromellose with an esterification agent in the presence of a catalyst to obtain a reaction solution containing crude hypromellose phthalate, a precipitation step of mixing the reaction solution with water to precipitate the crude hypromellose phthalate, thereby obtaining a hypromellose phthalate suspension, a liquid removal step of removing a liquid from the hypromellose phthalate suspension with a centrifugal decanter to obtain liquid-removed hypromellose phthalate, and a drying step of drying the liquid-removed hypromellose phthalate.

Abstract: An anti-allergenic composition comprising from about 0.01% to about 50% by weight of a polyphenol, from about 0.01% to about 50% by weight of a terpene compound, and from about 0.001% to about 10% by weight of a glycolipid. The polyphenol has a flavanol derivative. The terpene compound can be selected from the group consisting of a terpene, terpinene, a terpene derivative and combinations thereof. In an embodiment, the sphingolipid comprises about 0.2% phytosphingosine.

Abstract: Among other things, compositions, kits, and methods for epilepsy therapy using a process for treating calcinosis manifested in Neurocysticercosis, Tuberous Sclerosis Complex, and Sturge-Weber Syndrome; an automated platform for real-time diagnosis and treatment of calcinosis comprising a computer-implemented method for using predictive analytics for administering a novel drug, Kamini™, to human patients generated at least in part from information that has been accumulated automatically from on-line resources.

Abstract: Hair treatment agents are provided herein. The hair treatment agent contains at least one fatty alcohol; at least one cationic surfactant; at least one divalent or trivalent metal salt; at least one silver salt selected from silver acetate, silver adipate, silver citrate, silver galactarate, silver gluconate, silver lactate, silver malate, silver mandelate, silver salicylate, silver succinate, silver sulfate, and silver tartrate; and at least one organic acid selected from adipic acid, succinic acid, citric acid, acetic acid, galactaric acid, gluconic acid, hydroxysuccinic acid, mandelic acid, lactic acid, salicylic acid, sulfuric acid, and tartaric acid. The hair treatment agent reduces or prevents the fading of color from dyed hair.

Abstract: The instant disclosure relates to masks, methods for making masks, methods for improving film elasticity of masks, and to methods of treating skin with masks. The masks are formed by applying a mask base composition onto a surface, the mask base composition comprising: (i) alginic acid and/or a salt thereof; (ii) hectorite (lithium magnesium sodium silicate); (iii) one or more water-soluble solvents; and (iv) water; and exposing the mask base composition to a crosslinking composition for a time sufficient to crosslink the alginic acid and/or a salt thereof and form a final mask, the crosslinking composition being an aqueous liquid comprising (i) one or more polyvalent cations of one or more metals; and (ii) water. The instant disclosure further relates to masks formed by the disclosed methods and to kits comprising the compositions for making and/or using the masks.

Abstract: Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.

Abstract: The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

Abstract: Benzotriazole phenols with substituents either ortho to the phenol hydroxyl group and/or para to the phenol hydroxyl group can be prepared from the unsubstituted benzotriazole phenol by coupling reactions. The ortho substituent group can be a simple alkoxy or amino group, or the ortho substituent group can be a linking group, linking the benzotriazole phenol to another benzotriazole phenol group.

Abstract: The present invention relates to a method for mass-production of viniferin using stevioside from cell culture of grape tree tissue. Viniferin is known to be effective for protection of liver, anticancer, antioxidant, and skin whitening, have an effect of inhibiting oxidation of low-density lipoprotein and high-density lipoprotein and inhibiting the proliferation and migration of vascular smooth muscle cells. Therefore, the present invention is very useful for the mass production of viniferin among the useful substances (stilbene compounds) from a callus derived from the anther tissue of the grape plant, which is very important for the related industries.

Abstract: A porous bionic skull repairing material includes a polymer material, whose structure is consistent with that of a human skull. The surface layers of the porous bionic skull repairing material are dense layers which are composed of non-degradable or degradable polymer materials and has blind holes having an asymmetric structure, and the inner layer of the porous bionic skull repairing material is a loose layer which has a porous structure. The repairing material can be molded by adopting a mixed mould pressing method or a 3D printing method, simulates a bone structure, with two dense sides and a loose middle, of a human skull to the greatest extent.

Abstract: Methods of treating a methicillin-resistant Staphylococcus aureus (MRSA) infection or a Staphylococcus pseudintermedius infection in subject in need thereof are provided, the methods comprising administering to the subject an effective amount of a topical gel composition comprising vitamin E d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS); and at least one lipophile. Compositions, methods of manufacture, and methods of use in inhibiting microbial growth are also provided.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.

Abstract: A deodorant stick comprising at least 25% by weight liquid triglyceride; a primary antimicrobial having a water solubility of at most about 90 g/L at 25° C.; a fragrance composition comprising at least about 50% natural oils, essential oils, or a combination thereof; and a primary structurant with a melting point of at least 50° C.; said deodorant stick being free of an aluminum salt; and said deodorant stick having a hardness from about 70 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: A method for growing polarized endometrial cells, said method comprising: (a) disposing endometrial cells on a scaffold, said scaffold comprising a silica-based glass composition, characterized by multi-modal porosity, said scaffold being to define a top side and a bottom side; (b) providing nutrients to said top and bottom sides of said scaffold and an environment to grow polarized endometrial cells on said scaffold.

Abstract: This invention relates to medical science and pharmaceutical technology. A new type of finished pharmaceutical form with individual medicine dosing capability is described comprising a storage container and a carrier on which the medicine is applied. Methods of production and use of the finished pharmaceutical form for individual medicine dosing are suggested.

Abstract: Embodiments of the invention generally relate to supplements for treating fibromyalgia and symptoms associated with fibromyalgia, wherein the nutritional supplement is administered for at least one of following: fatigue, chronic pain, morning stiffness, headaches, and problems with thinking and memory.

Abstract: There are provided HPMCAS (hypromellose acetate succinate) having such a property that a solution of the HPMCAS in a solvent has a controlled viscosity; and a method for producing the HPMCAS. More specifically, provided are HPMCAS having such property that a solution of 10 parts by weight of the HPMCAS in 100 parts by weight of a mixed solvent having a weight ratio of methylene chloride to methanol of 1:1 has a viscosity at 20° C. of 135 mPa·s or less; and a method for producing the HPMCAS including an esterification step of adding acetic anhydride and succinic anhydride to a solution of hypromellose in glacial acetic acid in the presence of sodium acetate to obtain a reaction product mixture, wherein the succinic anhydride is added intermittently, and a precipitation step of mixing the reaction product mixture with water to precipitate the HPMCAS.